Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II metronomic oral vinorelbine plus bevacizumab as first-line treatment for metastatic breast cancer
2010-022183-12Phase 2Terminated
- Sponsor
- European Institute of Oncology
- Start
- Nov 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinorelbine and bevacizumab in breast cancer, sponsored by European Institute of Oncology. Primary endpoints: Overall response rate and Clinical benefit rate. Started Nov 2010; status: terminated.
02
Drugs
vinorelbinebevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-022183-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022183-12.